



INDIANA UNIVERSITY

SCHOOL OF MEDICINE

Bowen Center for Health Workforce Research and Policy

Intent of Survey Tool: To identify perceived provider barriers in obtaining a DATA 2000 Waiver

Recommended audience: Health system executives (including human resources, operating officers, workforce specialists/recruiters, etc.)

Organizational Perspective on Medication-Assisted Treatment (MAT)

- To what extent is MAT or buprenorphine medication management a part of the service line at your facility?
- How would you describe your organization's perspective on MAT?
- Has the implementation of MAT impacted other services offered by your organization? (ex: screening, addiction counseling, etc.)
- Considering your boarder community, are you aware of any other providers or organizations offering MAT offered in your community?

Provider Perspective on DATA 2000 Waiver

- How would you describe the provider perspective on MAT in your organization?
 - (Potential themes as identified by the literature):
 - Provider awareness of DATA 2000 Waiver
 - Network/hospital culture
 - Availability of supportive mental health services
 - Reimbursement for MAT
 - Provider time/costs
 - Time required to complete training/obtain waiver
 - Hesitation about increasing service line to include MAT due to full panel
 - General provider hesitation (ethical reservations, etc.)
- Do you believe the provider perspective on DATA 2000 Waiver differs by specialty (i.e. primary care vs. other specialties)
- Are you aware of any financial incentives for providers to obtain a DATA 2000 Waiver or to offer MAT services?
- Among the providers that currently hold DATA 2000 waivers, do you believe that obtaining their waiver has changed their practice in any way?
- Can you describe any specific concerns that waived providers have expressed regarding prescribing buprenorphine?

Literature Reviewed

Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. *Journal of general internal medicine*. 2007 Sep 1;22(9):1325-9.

Duncan LG, Mendoza S, Hansen H. Buprenorphine maintenance for opioid dependence in public sector healthcare: benefits and barriers. *Journal of addiction medicine and therapeutic science*. 2015;1(2):31.

Turner L, Kruszewski SP, Alexander GC. Trends in the use of buprenorphine by office-based physicians in the United States, 2003–2013. *The American journal on addictions*. 2015 Jan;24(1):24-9.

Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, Alford DP. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. *Journal of general internal medicine*. 2008 Sep 1;23(9):1393-8.